Vaccine Progress and What’s Next - a podcast by Goldman Sachs

Salveen Richter, lead analyst for the US Biotechnology sector in Goldman Sachs Research, talks about Pfizer’s clinical-trial results for its COVID-19 vaccine and the obstacles that still lie ahead for FDA approval and widespread distribution.

Further episodes of Goldman Sachs Exchanges

Further podcasts by Goldman Sachs

Website of Goldman Sachs